Orchid Asia Reaches USD1.1b First Close for Fund VIII

Orchid Asia has reached a USD1.1b first close for Fund VIII. The vehicle, which has an initial target of USD1.6b, will provide growth capital to companies looking to build franchises in the consumer, technology, education and healthcare sectors in China. Read more… Read More

Fortune Capital Reaches ~USD858m First Close for CNY Fund

Fortune Capital has reached a CNY5.5b (~USD858m) first close for its CNY-denominated fund targeting CNY6.8b (~USD1.1b). Fortune invests across multiple stages in both traditional and high-tech industries and the latest fund will follow the firm’s existing strategy. Read more… Read More

Sequoia China, China Merchants Health, Greenwoods & WuXi Apptec Lead USD188m Round for Chinese mRNA Specialist Stemirna

Sequoia Capital China, China Merchants Health, Greenwoods Asset Management and Wuxi AppTec led a CNY1.2b (~USD188m) round for Stemirna Therapeutics, a China-based mRNA drugs and vaccines developer, with participation from OrbiMed, Advantech Capital, China Reform Fund, CMB International, Kaili Yifang Capital Management, Forebright Capital, CTS Capital and CITIC Securities Investment. Read More



(default archive template)